My ePortfolio Register   

AACR 2011 /
AACR 2011: New Phase I targeted cancer drugs

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.04.11
Views: 6326

Dr Lori Friedman - Genentech, California, USA

Dr Lori Friedman, director of cancer signalling and translational oncology at Genentech, speaks about a session at the 2011 AACR congress where a number of previously undisclosed drugs in Stage I clinical trials were presented. The first drug discussed was a molecule which targets FGFR1, FGFR2 and FGFR3 in order to combat gastric and haematological malignancies. The second is a highly specific small molecule to target HER2. This drug is particularly exciting as it is able to cross from the blood into the brain. Due to this property it may be useful in treatment of HER2 positive breast cancer that has metastasised into the brain. Finally Dr Friedman talks about a drug which targets the ALK gene responsible for a subset of non-small lung cancer. Pfizer have previously developed a first generation drug to target both c-MET and ALK but this second generation drug is more specific and targets only ALK.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence